At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 2, 2026 at 16:05 ET
Theriva Biologics sold its SYN-004 (ribaxamase), SYN-007, and SYN-006 antibiotic-degrading enzyme portfolio to Biossil Labs for a $350,000 upfront payment, with potential regulatory milestones up to $3 million, sales milestones up to $88 million, low single-digit royalties capped at $250 million, and a low-double-digit percentage of license consideration. The transaction closed concurrently with the agreement on October 30, 2026, and Theriva also amended its existing agreement with PREV ABR LLC, paying $140,000 at closing and agreeing to share a portion of future proceeds from the Biossil deal, subject to a $13 million cap. The sale allows Theriva to focus on its oncolytic adenovirus platform (VCN-01) while retaining upside through contingent payments.
- Theriva sold its SYN-004 (ribaxamase), SYN-007, and SYN-006 assets to Biossil Labs for a $350,000 upfront payment.
- Theriva is eligible for up to $3 million in regulatory milestones, up to $88 million in sales milestones, low single-digit royalties capped at $250 million, and a low-double-digit percentage of license consideration.
- The closing occurred concurrently with the execution of the Asset Purchase and Sale Agreement on October 30, 2026.
- Theriva amended its 2012 agreement with PREV ABR LLC, paying $140,000 at closing and agreeing to share 50% of regulatory/sales milestones, 33.33% of royalties, and 50% of other consideration from the Biossil deal, subject to a $13 million aggregate cap.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access